New York firm Homeocare Laboratories Inc. is “particularly concerning” to the US Food and Drug Administration because its manufactured OTC products containing toxic ingredients, some indicated for children, with poor documentation, testing and cleaning procedures.
A warning letter submitted on 22 June by the Office of Regulatory Affairs’ Division of Pharmaceutical Quality Operations I in New Jersey notes that Homeocare Labs indicated to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?